| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lilly Research Laboratories (A.K., Y.B.C., M.M., A.F., P.A.G.-D., J.E.H., D.L., D.D.Y., J.G.H., S.R.J., P.E.), Eli Lilly & Company, Indianapolis, Indiana 46285; and Millennium Pharmaceutical Inc. (Y.Q., C.C.F.), Cambridge, Massachusetts 02139
Address all correspondence and requests for reprints to: Anja Köster, Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, Indiana 46225. E-mail: koester_anja{at}lilly.com.
Lipoprotein lipase (LPL) is a key regulator of triglyceride clearance. Its coordinated regulation during feeding and fasting is critical for maintaining lipid homeostasis and energy supply. Angiopoietin-like (Angptl)3 and Angptl4 are secreted proteins that have been demonstrated to regulate triglyceride metabolism by inhibiting LPL. We have taken a targeted genetic approach to generate Angptl4- and Angptl3-deficient mice as well as transgenic mice overexpressing human Angptl4 in the liver. The Angptl4 transgenic mice displayed elevated plasma triglycerides and reduced postheparin plasma (PHP) LPL activity. A purified recombinant Angptl4 protein inhibited mouse LPL and recombinant human LPL activity in vitro. In contrast to the transgenic mice, Angptl4-deficient mice displayed hypotriglyceridemia and increased PHP LPL activity, with greater effects in the fasted compared with the fed state. Angptl3-deficient mice also displayed hypotriglyceridemia with elevated PHP LPL activity, but these mice showed a greater effect in the fed state. Mice deficient in both Angptl proteins showed an additive effect on plasma triglycerides and did not survive past 2 months of age. Our results show that Angptl3 and Angptl4 function to regulate circulating triglyceride levels during different nutritional states and therefore play a role in lipid metabolism during feeding/fasting through differential inhibition of LPL.
This article has been cited by other articles:
![]() |
G. M. Dallinga-Thie, A. J. Zonneveld-de Boer, L. C. van Vark-van der Zee, R. van Haperen, T. van Gent, H. Jansen, R. De Crom, and A. van Tol Appraisal of hepatic lipase and lipoprotein lipase activities in mice J. Lipid Res., December 1, 2007; 48(12): 2788 - 2791. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Andrew, V. Bernardo, L. A. Warnke, J. C. Davey, T. Hampton, R. A. Mason, J. E. Thorpe, M. A. Ihnat, and J. W. Hamilton Exposure to Arsenic at Levels Found in U.S. Drinking Water Modifies Expression in the Mouse Lung Toxicol. Sci., November 1, 2007; 100(1): 75 - 87. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Lichtenstein, J. F.P. Berbee, S. J. van Dijk, K. W. van Dijk, A. Bensadoun, I. P. Kema, P. J. Voshol, M. Muller, P. C.N. Rensen, and S. Kersten Angptl4 Upregulates Cholesterol Synthesis in Liver via Inhibition of LPL- and HL-Dependent Hepatic Cholesterol Uptake Arterioscler. Thromb. Vasc. Biol., November 1, 2007; 27(11): 2420 - 2427. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. A. Moen, A. P. Tholens, P. J. Voshol, W. de Haan, L. M. Havekes, P. Gargalovic, A. J. Lusis, K. W. van Dyk, R. R. Frants, M. H. Hofker, et al. The Hyplip2 locus causes hypertriglyceridemia by decreased clearance of triglycerides J. Lipid Res., October 1, 2007; 48(10): 2182 - 2192. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Wu, L. Zhang, J. Gupta, G. Olivecrona, and T. Olivecrona A transcription-dependent mechanism, akin to that in adipose tissue, modulates lipoprotein lipase activity in rat heart Am J Physiol Endocrinol Metab, October 1, 2007; 293(4): E908 - E915. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Desai, E-C. Lee, K. Chung, C. Gao, J. Gay, B. Key, G. Hansen, D. Machajewski, K. A. Platt, A. T. Sands, et al. Lipid-lowering effects of anti-angiopoietin-like 4 antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice PNAS, July 10, 2007; 104(28): 11766 - 11771. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Galaup, A. Cazes, S. Le Jan, J. Philippe, E. Connault, E. Le Coz, H. Mekid, L. M. Mir, P. Opolon, P. Corvol, et al. Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness PNAS, December 5, 2006; 103(49): 18721 - 18726. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Sukonina, A. Lookene, T. Olivecrona, and G. Olivecrona Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue PNAS, November 14, 2006; 103(46): 17450 - 17455. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. G. Schaap, M. C. Nierman, J. F. P. Berbee, H. Hattori, P. J. Talmud, S. F. C. Vaessen, P. C. N. Rensen, R. A. F. M. Chamuleau, J. A. Kuivenhoven, and A. K. Groen Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia J. Lipid Res., October 1, 2006; 47(10): 2333 - 2339. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Fugier, J.-J. Tousaint, X. Prieur, M. Plateroti, J. Samarut, and P. Delerive The Lipoprotein Lipase Inhibitor ANGPTL3 Is Negatively Regulated by Thyroid Hormone J. Biol. Chem., April 28, 2006; 281(17): 11553 - 11559. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mandard, F. Zandbergen, E. van Straten, W. Wahli, F. Kuipers, M. Muller, and S. Kersten The Fasting-induced Adipose Factor/Angiopoietin-like Protein 4 Is Physically Associated with Lipoproteins and Governs Plasma Lipid Levels and Adiposity J. Biol. Chem., January 13, 2006; 281(2): 934 - 944. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |